Goldman Sachs Future Health Care Equity ETF (GDOC) Holdings
GDOC holdings summary
as of Oct 25, 2026- Holdings
- 41 positions listed
- Top 10 weight
- 54.5% of net assets
- Effective holdings
- 20 equal-weight equivalent
- Largest holding
- LLY 13.81% Eli Lilly and Company
- Annual turnover
- 27.5% of the portfolio traded
All GDOC holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly and Company | Healthcare | 13.81% | $2.8M | $1.12T | 42.2 |
| 2 | MRK | Merck & Co., Inc. | Healthcare | 6.99% | $1.4M | $360.08B | 115.8 |
| 3 | UNH | UnitedHealth Group Incorporated | Healthcare | 6.04% | $1.2M | $360.32B | 25.8 |
| 4 | JNJ | Johnson & Johnson | Healthcare | 5.83% | $1.2M | $615.87B | 38.8 |
| 5 | VRTX | Vertex Pharmaceuticals Incorporated | Healthcare | 4.15% | $827,256.04 | $126.66B | 28.9 |
| 6 | A | Agilent Technologies, Inc. | Healthcare | 3.81% | $759,541.22 | $48.77B | 34.1 |
| 7 | TMO | Thermo Fisher Scientific Inc. | Healthcare | 3.76% | $747,969.95 | $255.13B | 37.1 |
| 8 | GH | Guardant Health, Inc. | Healthcare | 3.51% | $699,016.12 | $21.28B | — |
| 9 | EW | Edwards Lifesciences Corporation | Healthcare | 3.38% | $673,802.31 | $49.92B | 51.5 |
| 10 | DXCM | DexCom, Inc. | Healthcare | 3.25% | $647,054.95 | $32.47B | 34.1 |
| 11 | GILD | Gilead Sciences, Inc. | Healthcare | 3.08% | $614,113.68 | $193.67B | — |
| 12 | LONN | Lonza Group AG | Healthcare | 3.07% | $611,345.34 | — | — |
| 13 | NTRA | Natera, Inc. | Healthcare | 2.82% | $562,610.59 | $56.71B | — |
| 14 | COR | Cencora | Healthcare | 2.77% | $552,632.61 | $65.06B | 25.3 |
| 15 | ISRG | Intuitive Surgical, Inc. | Healthcare | 2.73% | $542,973.29 | $150.74B | 48.9 |
| 16 | ROIV | Roivant Sciences Ltd. | Healthcare | 2.61% | $520,726.98 | $24.22B | — |
| 17 | VEEV | Veeva Systems Inc. | Healthcare | 2.29% | $455,661.00 | $50.25B | 50.9 |
| 18 | AZN | AstraZeneca PLC | Healthcare | 2.17% | $431,801.48 | — | — |
| 19 | MTD | Mettler-Toledo International Inc. | Healthcare | 2.07% | $412,542.59 | $32.51B | 36.6 |
| 20 | RGEN | Repligen Corporation | Healthcare | 2.06% | $409,296.26 | $11.14B | 240.3 |
| 21 | RPRX | Royalty Pharma plc | Healthcare | 1.78% | $353,710.36 | $35.22B | 32.4 |
| 22 | ABBV | AbbVie Inc. | Healthcare | 1.50% | $297,825.72 | $504.37B | 80.6 |
| 23 | GALD | Galderma Group N | Healthcare | 1.50% | $297,805.80 | — | — |
| 24 | BSX | Boston Scientific Corporation | Healthcare | 1.46% | $291,432.64 | $64.33B | 18.0 |
| 25 | DGX | Quest Diagnostics Incorporated | Healthcare | 1.42% | $282,271.23 | $25.94B | 24.6 |
| 26 | TXG | 10x Genomics, Inc. | Healthcare | 1.37% | $272,811.07 | $9.10B | — |
| 27 | INSM | Insmed Incorporated | Healthcare | 1.36% | $270,221.97 | $21.02B | — |
| 28 | CYTK | Cytokinetics, Incorporated | Healthcare | 1.34% | $266,258.66 | $8.61B | — |
| 29 | BBIO | BridgeBio Pharma, Inc. | Healthcare | 1.22% | $242,299.56 | $12.98B | — |
| 30 | ARGX | argenx SE | Healthcare | 1.02% | $203,841.53 | $51.51B | 31.2 |
| 31 | MDGL | Madrigal Pharmaceuticals, Inc. | Healthcare | 0.83% | $165,443.24 | $10.39B | — |
| 32 | DNTH | Dianthus Therapeutics, Inc. | Healthcare | 0.57% | $113,482.07 | $4.03B | — |
| 33 | DIM | Sartorius Stedim Biotech SA | Healthcare | 0.55% | $109,797.59 | — | — |
| 34 | SYRE | Spyre Therapeutics, Inc. | Healthcare | 0.55% | $108,562.79 | $7.47B | — |
| 35 | MRNA | Moderna, Inc. | Healthcare | 0.45% | $89,064.91 | $87.04B | — |
| 36 | KYMR | Kymera Therapeutics, Inc. | Healthcare | 0.40% | $79,644.58 | $8.62B | — |
| 37 | RYTM | Rhythm Pharmaceuticals, Inc. | Healthcare | 0.40% | $79,067.01 | $5.91B | — |
| 38 | PRAX | Praxis Precision Medicines, Inc. | Healthcare | 0.32% | $64,050.25 | $6.75B | — |
| 39 | KARD | Kardigan, Inc. | Healthcare | 0.32% | $63,671.85 | $1.22B | — |
| 40 | DFTX | Definium Therapeutics, Inc. | Healthcare | 0.31% | $62,516.71 | $4.31B | — |
| 41 | CGON | CG Oncology, Inc. | Healthcare | 0.30% | $60,027.20 | $5.31B | — |
Weights as a percentage of net assets. Value held = weight × net assets ($19.9M). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
GDOC sector breakdown
Sum of the weights of the holdings in each sector.
GDOC top industries
GDOC overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| IYH | iShares U.S. Healthcare ETF | 50.1% | 24 of 99 | 0.39% |
| XLV | Health Care Select Sector SPDR Fund | 50.0% | 18 of 60 | 0.09% |
| TRUH | VanEck Healthcare TruSector ETF | 49.6% | 18 of 60 | — |
| FHLC | Fidelity MSCI Health Care ETF | 48.3% | 35 of 334 | 0.07% |
| VHT | Vanguard Health Care ETF | 48.0% | 34 of 406 | 0.10% |
| IXJ | iShares Global Healthcare ETF | 43.9% | 23 of 106 | 0.42% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the GDOC portfolio
Goldman Sachs Future Health Care Equity ETF holds 41 positions. The ten largest make up 54.5% of the fund, so it behaves like a portfolio of about 20 equally weighted stocks. The biggest positions are Eli Lilly and Company (13.81%), Merck & Co., Inc. (6.99%), UnitedHealth Group Incorporated (6.04%), Johnson & Johnson (5.83%), Vertex Pharmaceuticals Incorporated (4.15%).
By sector, Healthcare is 99.2%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 25, 2026; positions change as the fund rebalances.
Related: GDOC chart, GDOC performance, GDOC dividends, GDOC valuation, GDOC overview.
GDOC holdings FAQ
How many holdings does GDOC have?
GDOC holds 41 positions as of October 25, 2026.
What are the top 10 holdings of GDOC?
The ten largest holdings are Eli Lilly and Company (13.81%), Merck & Co., Inc. (6.99%), UnitedHealth Group Incorporated (6.04%), Johnson & Johnson (5.83%), Vertex Pharmaceuticals Incorporated (4.15%), Agilent Technologies, Inc. (3.81%), Thermo Fisher Scientific Inc. (3.76%), Guardant Health, Inc. (3.51%), Edwards Lifesciences Corporation (3.38%), DexCom, Inc. (3.25%). Together they are 54.5% of the fund.
What percentage of GDOC is Eli Lilly and Company?
Eli Lilly and Company is the largest holding at 13.81% of net assets, about $2.8M of the fund's $19.9M.
How concentrated is GDOC?
The top 10 holdings are 54.5% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) GDOC behaves like a portfolio of about 20 equally weighted stocks.